
Enochian Biosciences ENOB
Country |
|
IPO year |
- |
Industry |
Biotechnology |
Stock Exchange |
NASDAQ CAPITAL |
Shares |
3.36 M |
Market Cap[1] |
$ 40.5 M |
EBITDA (LTM) |
$ -8.36 M |
P/E (LTM) |
- |
P/S (LTM) |
779.878501 |
EPS (LTM) |
-0.13 |
Other stocks of industry "Biotechnology"
| Issuer | Price | % 24h | Market Cap | Exchange | Country | |
|---|---|---|---|---|---|---|
|
Innate Pharma S.A.
IPHA
|
$ 1.4 | -1.76 % | $ 125 M | Nasdaq Global Select Market | ||
|
Seneca Biopharma, Inc.
SNCA
|
- | -1.19 % | $ 28.7 M | Nasdaq Capital Market | ||
|
BioMarin Pharmaceutical
BMRN
|
$ 56.14 | -1.74 % | $ 10.8 B | Nasdaq Global Select Market,SPB | ||
|
Matinas BioPharma Holdings
MTNB
|
$ 1.11 | -7.0 % | $ 6.08 M | NYSE American | ||
|
Enanta Pharmaceuticals
ENTA
|
$ 10.06 | -5.54 % | $ 215 K | Nasdaq Global Select Market,SPB | ||
|
Milestone Pharmaceuticals
MIST
|
$ 0.69 | -10.54 % | $ 73.3 M | Nasdaq Global Select Market | ||
|
Kiniksa Pharmaceuticals, Ltd.
KNSA
|
$ 88.15 | -8.29 % | $ 6.54 B | Nasdaq Global Select Market | ||
|
Lipocine
LPCN
|
$ 1.52 | 5.56 % | $ 8.28 M | Nasdaq Global Select Market | ||
|
Seres Therapeutics
MCRB
|
$ 2.09 | -2.63 % | $ 18.5 M | Nasdaq Global Select Market | ||
|
Madrigal Pharmaceuticals
MDGL
|
$ 400.26 | -0.04 % | $ 8.98 B | Nasdaq Global Select Market,SPB | ||
|
CEL-SCI Corporation
CVM
|
$ 1.35 | -2.88 % | $ 10.8 M | NYSE American,SPB | ||
|
Inventiva S.A.
IVA
|
$ 3.65 | -5.68 % | $ 218 M | Nasdaq Global Market | ||
|
MeiraGTx Holdings plc
MGTX
|
$ 8.51 | -9.71 % | $ 684 M | Nasdaq Global Select Market | ||
|
Eton Pharmaceuticals
ETON
|
$ 47.29 | -6.76 % | $ 1.27 B | Nasdaq Global Market | ||
|
IDEAYA Biosciences
IDYA
|
$ 30.63 | -5.35 % | $ 2.71 B | Nasdaq Global Select Market | ||
|
Lantern Pharma
LTRN
|
$ 0.55 | -5.33 % | $ 5.99 M | Nasdaq Global Select Market | ||
|
Foghorn Therapeutics
FHTX
|
$ 1.9 | -9.52 % | $ 120 M | Nasdaq Global Market | ||
|
Minerva Neurosciences
NERV
|
$ 2.3 | -10.7 % | $ 19.5 M | Nasdaq Global Market | ||
|
Kamada Ltd.
KMDA
|
$ 6.89 | -7.14 % | $ 397 M | Nasdaq Global Select Market | ||
|
Neurocrine Biosciences
NBIX
|
$ 159.9 | -3.7 % | $ 15.9 B | Nasdaq Global Select Market,SPB | ||
|
Nanobiotix S.A.
NBTX
|
$ 29.92 | 0.74 % | $ 1.43 T | Nasdaq Global Select Market | ||
|
Mereo BioPharma Group plc
MREO
|
$ 0.28 | -7.49 % | $ 223 M | Nasdaq Global Select Market | ||
|
Maravai LifeSciences Holdings
MRVI
|
$ 6.94 | -10.1 % | $ 1 B | Nasdaq Global Select Market | ||
|
Lexicon Pharmaceuticals
LXRX
|
$ 1.61 | 8.78 % | $ 585 M | Nasdaq Global Select Market | ||
|
Moleculin Biotech
MBRX
|
$ 8.72 | 3.07 % | $ 10.3 M | Nasdaq Global Select Market | ||
|
Nurix Therapeutics
NRIX
|
$ 14.83 | -7.02 % | $ 1.29 B | Nasdaq Global Select Market,SPB | ||
|
Nkarta
NKTX
|
$ 1.59 | -8.38 % | $ 118 M | Nasdaq Global Select Market | ||
|
MacroGenics
MGNX
|
$ 2.24 | -3.25 % | $ 141 M | Nasdaq Global Select Market | ||
|
ImmuCell Corporation
ICCC
|
$ 9.88 | -4.77 % | $ 89.2 M | Nasdaq Global Select Market | ||
|
Nuvation Bio
NUVB
|
$ 4.19 | -11.42 % | $ 1.43 B | NYSE | ||
|
Novo Nordisk A/S
NVO
|
$ 40.27 | -4.52 % | $ 179 B | NYSE | ||
|
Marker Therapeutics
MRKR
|
$ 0.9 | -11.24 % | $ 13.8 M | Nasdaq Global Market | ||
|
NextCure
NXTC
|
$ 5.16 | -12.39 % | $ 14.7 M | Nasdaq Global Select Market | ||
|
Olema Pharmaceuticals
OLMA
|
$ 6.89 | -8.62 % | $ 599 M | Nasdaq Global Select Market | ||
|
Kymera Therapeutics
KYMR
|
$ 124.88 | -8.34 % | $ 10.6 B | Nasdaq Global Market | ||
|
Oragenics
OGEN
|
$ 0.34 | -9.47 % | $ 733 K | NYSE American | ||
|
Ovid Therapeutics
OVID
|
$ 2.59 | -5.66 % | $ 337 M | Nasdaq Global Select Market | ||
|
Passage Bio
PASG
|
$ 3.44 | -2.14 % | $ 11 M | Nasdaq Global Select Market | ||
|
Vaxcyte
PCVX
|
$ 62.47 | -4.89 % | $ 8.5 B | Nasdaq Global Select Market | ||
|
Precigen
PGEN
|
$ 4.2 | -16.94 % | $ 1.31 B | Nasdaq Global Select Market | ||
|
Phio Pharmaceuticals Corp.
PHIO
|
$ 0.81 | -7.25 % | $ 4.85 M | Nasdaq Capital Market | ||
|
Praxis Precision Medicines
PRAX
|
$ 262.42 | -7.85 % | $ 5.91 B | Nasdaq Global Select Market,SPB | ||
|
Prelude Therapeutics Incorporated
PRLD
|
$ 3.55 | -12.99 % | $ 273 M | Nasdaq Global Select Market | ||
|
ProQR Therapeutics N.V.
PRQR
|
$ 1.34 | -5.32 % | $ 141 M | Nasdaq Global Market | ||
|
Ocular Therapeutix
OCUL
|
$ 6.48 | -9.31 % | $ 1.21 B | Nasdaq Global Select Market | ||
|
PolyPid Ltd.
PYPD
|
$ 5.8 | -0.34 % | $ 94.8 M | Nasdaq Global Select Market | ||
|
Summit Therapeutics
SMMT
|
$ 14.17 | -12.37 % | $ 10.6 B | Nasdaq Global Select Market | ||
|
Outlook Therapeutics
OTLK
|
$ 0.44 | -4.63 % | $ 15.3 M | Nasdaq Global Select Market | ||
|
uniQure N.V.
QURE
|
$ 20.96 | -9.01 % | $ 1.21 B | Nasdaq Global Select Market | ||
|
Ultragenyx Pharmaceutical
RARE
|
$ 15.55 | -9.38 % | $ 1.53 B | Nasdaq Global Select Market,SPB |
References
- Pavone, P. (2019). Market capitalization and financial variables: Evidence from Italian listed companies. International Journal of Academic Research Business and Social Sciences, 9(3), 1356-1371.